David Chang Sells 95,269 Shares of Allogene Therapeutics (NASDAQ:ALLO) Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO) CEO David Chang sold 95,269 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $1.80, for a total transaction of $171,484.20. Following the transaction, the chief executive officer directly owned 5,185,862 shares in the company, valued at approximately $9,334,551.60. This represents a 1.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Allogene Therapeutics Trading Down 9.4%

Shares of NASDAQ ALLO opened at $1.63 on Friday. The firm has a market capitalization of $366.31 million, a P/E ratio of -1.66 and a beta of 0.60. The firm’s 50-day moving average price is $1.52 and its 200-day moving average price is $1.32. Allogene Therapeutics, Inc. has a 1-year low of $0.86 and a 1-year high of $3.78.

Allogene Therapeutics (NASDAQ:ALLO) last issued its earnings results on Thursday, November 6th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.04. Equities research analysts forecast that Allogene Therapeutics, Inc. will post -1.28 EPS for the current year.

Hedge Funds Weigh In On Allogene Therapeutics

Hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. raised its holdings in shares of Allogene Therapeutics by 177.9% in the first quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company’s stock valued at $8,547,000 after purchasing an additional 3,747,397 shares during the last quarter. Millennium Management LLC grew its position in Allogene Therapeutics by 125.6% in the 3rd quarter. Millennium Management LLC now owns 3,390,026 shares of the company’s stock worth $4,204,000 after purchasing an additional 1,887,302 shares in the last quarter. Two Sigma Investments LP increased its stake in Allogene Therapeutics by 109.7% in the 3rd quarter. Two Sigma Investments LP now owns 3,383,644 shares of the company’s stock valued at $4,196,000 after buying an additional 1,770,419 shares during the last quarter. UBS Group AG lifted its position in shares of Allogene Therapeutics by 75.1% during the 3rd quarter. UBS Group AG now owns 3,571,157 shares of the company’s stock worth $4,428,000 after buying an additional 1,532,238 shares in the last quarter. Finally, Primecap Management Co. CA lifted its position in shares of Allogene Therapeutics by 23.8% during the 3rd quarter. Primecap Management Co. CA now owns 7,079,308 shares of the company’s stock worth $8,778,000 after buying an additional 1,360,168 shares in the last quarter. 83.63% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ALLO has been the topic of a number of research reports. UBS Group began coverage on Allogene Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating and a $8.00 target price on the stock. Wall Street Zen upgraded shares of Allogene Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, November 28th. JPMorgan Chase & Co. restated an “underweight” rating on shares of Allogene Therapeutics in a report on Friday, October 10th. Citigroup upgraded shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating in a report on Friday, January 9th. Finally, Citizens Jmp raised shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 target price for the company in a research report on Friday, January 9th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $8.40.

Allogene Therapeutics News Summary

Here are the key news stories impacting Allogene Therapeutics this week:

• Positive Sentiment: Company-reported progress in its CAR‑T trials and an update indicating an extended cash runway sparked a recent rally by reducing near‑term financing risk and keeping clinical milestones on the radar. Article Title
• Neutral Sentiment: Allogene announced participation in two investor conferences in Q1 2026 — a standard IR activity that gives the company chances to update investors but is not itself a catalyst for immediate clinical progress. Article Title
• Neutral Sentiment: Broader sector commentary highlights rapid innovation in immunotherapy and AI-driven oncology R&D — a positive backdrop for Allogene but not an immediate company‑specific driver. Article Title
• Negative Sentiment: Multiple insider sales were filed for Feb. 2 (including CEO David D. Chang selling ~95,269 shares at ~$1.80 and several C‑suite/SVP sales reported at ~$1.72–1.77). While each sale is a modest percentage of individual holdings, the cluster of senior executive sales is likely increasing selling pressure and contributing to today’s pullback. Article Title

About Allogene Therapeutics

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.